ABSTRACT
Importance The COVID-19 pandemic led many higher education institutions to close campuses during the 2020-21 academic year. As campuses prepared for a return to in-person education, many institutions were mandating vaccines for students and considering the same for faculty and staff. This paper demonstrates the effectiveness of such a strategy based on evidence from a mid-sized midwestern university.
Objective To determine whether high vaccination coverage can mitigate the spread of SARS-CoV-2, even in the presence of highly-transmissible variants and congregate living.
Setting This study was conducted at a mid-sized midwestern university during the spring 2021 semester.
Design The university developed a saliva-based surveillance program capable of high-throughput SARS-CoV-2 polymerase chain reaction testing and genomic sequencing with the capacity to deliver results in less than 24 hours. On April 7, 2021, the university announced a vaccine requirement for all students for the fall 2021 semester and announced the same requirement for faculty and staff on May 20, 2021. The university hosted an onsite mass vaccination clinic using the two-dose Pfizer-BioNTech vaccine April 8-15 and April 29 - May 6, 2021. Data from January 6 - May 20, 2021 were analyzed.
Participants This study includes 14,894 individuals from the university population who tested on campus for COVID-19 during the spring 2021 semester.
Main Outcomes and Measures Positive SARS-CoV-2 diagnosis was confirmed by quantitative reverse transcription–polymerase chain reaction (qRT-PCR) of saliva specimens and variant identity was assessed by qRT-PCR and next-generation sequencing (NGS) of viral genomes.
Results Between January and May 2021, the university conducted 196,185 COVID-19 tests and identified 1,603 positives – ∼89% students – with 687 identified via PCR of saliva specimens. The Alpha (B.1.1.7) variant constituted 44% of total positives sequenced. By May 20, 2021, 91% (10,068) of students, 92% (814) of faculty, and 72% (2,081) of staff were vaccinated. The 7-day rolling average of positive cases peaked at 37 cases on February 17 but declined to zero by May 14, 2021. The 7-day moving average of positive cases was inversely associated with the cumulative vaccination rate.
Conclusions and Relevance This study demonstrates the high effectiveness of robust vaccination programs even in the presence of highly-transmissible variants and congregate living.
Question How is the spread of COVID-19 affected by increasing rates of vaccination?
Findings We leverage 190,000+ COVID-19 surveillance tests including 1,603 positives for COVID-19 at a mid-sized midwestern university from January 6 – May 20, 2021. Genomic sequencing indicates that the Alpha (B.1.1.7) variant was first identified in early February and became the dominant variant by early March and the only variant resulting in positive cases by April. An increase in vaccination was associated with a dramatic decrease in COVID-19 cases in the campus population.
Meaning Mass vaccination efforts can effectively control the spread of SARS-CoV-2 even as highly-transmissible variants are introduced.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was fully funded internally by the University of Notre Dame (ND). All authors are ND employees. No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Notre Dame Human Subjects Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Datasets are available from the corresponding author upon reasonable request. All datasets have restricted access and are governed by an IRB at the University of Notre Dame.
